Equity
-€18,869
Debts exceed assets in financial year 2025.
PHARMFLY
Lifetime
20 annual accounts with figures on one time axis, 29 filings since 1997peak €64,646 (2017)
€32,018▲ 30.8%
lowest -€29,552 (2009)
€23,116▲ 47.5%
peak -€18,869 (2025)
-€18,869▲ €23,116
€72,453▼ 11.3%
Board1 name since 2021
1 director
Documentsfilings and deeds
29-04-20261 day before the deadline
2025micro format
Gross margin from €24,487 to €32,018Result from €15,672 to €23,116Equity from -€41,985 to -€18,869Investments €12,073Cash from €1,871 to €4,329
Key points
from the 2025 annual accountsTurnover
≈ €88,000 estimated
The micro format states no turnover.
Debts
€72,453 135% of the balance sheet
Suppliers 7%Taxes and wages 4%Other 89%
Investments
€12,073 3.2 × depreciation
Green is investment, beige is depreciation. Land and buildings stand 1797.9% higher than in 2024.
Filings
29 annual accounts since 1997
Five of the last ten came late. The 2020 accounts came latest: 49 days after the end of the period.
Position in the sector
-35.2%
Lower solvency than 91% of companies in real estate. Sector median 31.0% · 19,830 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 3,795 companies had the same profile as PHARMFLY has now. Each dot stands for 10 companies, two years later.
91.4%
were still trading
5.4%
stopped another way
2.7%
went bankrupt
Another 0.6% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,795 companies, not a prediction for PHARMFLY. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Capital increase of €260,000 to €291,300
Capital from €31,300 to €291,300, 2,576 new shares · General meeting of 26-06-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0457836931
Change of role: , from manager to director
Legal-form conversion: from private limited company (pre-2019) to private limited company · Director discharge: (manager) · General meeting of 22-11-2021 · Gazette deed
First establishment
Doorniksesteenweg 22, Avelgem
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PHARMFLY Avelgem | - | - | -35.2% | - |
| AAAcb Wavre | €84,975 | 23.3% | 67.4% | - |
| CITRACO Merksplas | - | - | 81.8% | - |
| RETAIL ADVICE & SUPPORT Schoten | - | - | -28.7% | - |
| GRAAF LODEWIJK Tongeren-Borgloon | - | - | 54.8% | - |
| Buildex Landen | - | - | 96.8% | - |
| AXION Zonhoven | €38,520 | 31.0% | 61.2% | - |
These companies have the same main activity as PHARMFLY: buying and selling of own real estate (NACE 68110). They are comparable in size and age: total assets between €50,900 and €80,700, founded between 1990 and 2002.
Official details
Source: KBO- Status
- Active since 18-04-1996Normal situation
- Activity
- Buying and selling of own real estateNACE 68110and 3 others
- Establishment unit
- 2.113.532.3078580 Avelgem, since 19-11-2002
- Financial year end
- 30 September
- Peppol
- Reachable since 09-12-2025
Annual accounts to 30-09-2025
- €53,584▲ 35.1%
- Filing
- Filed on 29-04-2026, 1 day before the end of the filing period
Insights on PHARMFLY
PHARMFLY files the micro format. That format states no turnover. The gross margin rose from €23,701 in 2006 to €32,018 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PHARMFLY
- What is the company number of PHARMFLY?
- The company number of PHARMFLY is 0457.836.931. The VAT number is the same number with BE in front: BE 0457.836.931.
- Where is PHARMFLY based?
- The registered office is at Doorniksesteenweg 22, 8580 Avelgem.Company details
- What does PHARMFLY do?
- According to the KBO register, the main activity is buying and selling of own real estate (NACE 68110).
- What is the legal form of PHARMFLY?
- PHARMFLY is a private limited company (BV).
- When was PHARMFLY founded?
- PHARMFLY was founded on 18-04-1996.
- Is PHARMFLY still active?
- Yes, PHARMFLY is an active enterprise in the KBO register.
- What is the turnover of PHARMFLY?
- The turnover in financial year 2025 is ≈ €88,000. This figure is estimated from the gross margin of €32,018 and 32 comparable companies (NACE 681). It probably lies between €48,000 and €180,000.Financials
- Is PHARMFLY profitable?
- In financial year 2025, PHARMFLY made a profit of €23,116.
- Where can I find the annual accounts of PHARMFLY?
- PHARMFLY filed 29 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMFLY due?
- PHARMFLY must file the annual accounts for financial year 2026 by 30-04-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.